Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. (Q34683871)

3 August 2017

1 reference

title

Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. (English)

1 reference

3 August 2017

3

Wiernik PH

1 reference

3 August 2017

Wadler S

1

1 reference

3 August 2017

Fuks JZ

series ordinal

2

1 reference

3 August 2017

language of work or name

1 reference

1 September 1986

1 reference

The Journal of Clinical Pharmacology

3 August 2017

published in

1 reference

3 August 2017

volume

26

1 reference

3 August 2017

issue

7

1 reference

3 August 2017

page(s)

491-509

1 reference

Why do cancer cells resist drugs?

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloidsin vivo. A new treatment principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Metabolism of 4'-modified analogs of doxorubicin. unique glucuronidation pathway for 4'-epidoxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Effects of the stereochemical configuration on the interaction of some daunomycin derivatives with DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Studies on the mode of interaction of 4'-epi-adriamycin and 4-demethoxy-daunomycin with DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Antitumor activity of esorubicin in human tumor clonogenic assay with comparisons to doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Phase I trial of esorubicin (4'deoxydoxorubicin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Phase I trial of 4'-deoxydoxorubicin given weekly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

The 1985 Walter Hubert lecture. Malignant cell differentiation as a potential therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Phase II trial of aclacinomycin A in acute leukemia and various solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Mitoxantrone: an active new agent in the treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Amsacrine (AMSA)--a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Interaction of antitumor drugs with human erythrocyte ghost membranes and mastocytoma P815: A spin label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

The toxicologic evaluation of marcellomycin--an antineoplastic anthracycline antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Human pharmacokinetics of marcellomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Superoxide-dependent formation of hydroxyl radicals in the presence of iron chelates: is it a mechanism for hydroxyl radical production in biochemical systems?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

Mitoxantrone as a first-line treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1986.TB02942.X

10.1002/J.1552-4604.1986.TB02942.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference